Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion Wins Race For High-Concentration Adalimumab

Receives Positive CHMP Opinion For 100mg/ml Biosimilar To Humira

Executive Summary

Celltrion expects to receive the world’s first approval for a high-concentration adalimumab biosimilar rival to Humira, after receiving a positive opinion from the EMA’s CHMP for its CT-P17 candidate.

You may also be interested in...



Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar

Celltrion has received a pan-European marketing authorization for its Yuflyma high-concentration adalimumab biosimilar, making it the first firm worldwide to register a 100mg/ml rival to the blockbuster Humira brand.

Celltrion Prepares Aflibercept For Phase III

Celltrion has announced that its latest biosimilar development project is progressing to Phase III trials, with its aflibercept rival to Eylea following recent advances for the Korean firm’s denosumab, omalizumab and ustekinumab candidates.

Celltrion Gets Ready For Denosumab Phase III

Celltrion has kicked off plans for a Phase III trial for its denosumab biosimilar rival to Prolia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel